H.C. Wainwright downgraded Acelyrin to Neutral from Buy with a price target of $6, down from $18. The second Phase 3 study of izokibep met the primary endpoint though efficacy does not support internally advancing, the analyst tells investors in a research note. The firm is not surprised with the company choosing to not advance izokibep further internally.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SLRN:
- ACELYRIN Refocuses on Thyroid Eye Disease, Cuts Workforce
- ACELYRIN, INC. Announces Positive Phase 3 Data for Izokibep in Hidradenitis Suppurativa; Focuses Strategy on Lonigutamab and Reports Second Quarter 2024 Financial Results
- SLRN Upcoming Earnings Report: What to Expect?
- ACELYRIN, INC. to Report Second Quarter 2024 Financial Results and Corporate Update on August 13, 2024
- Wells upgrades Acelyrin to Overweight with shares trading below cash